RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb, licensed an experimental drug and diagnostic agent for prostate cancer from Philochem AG for a $350 million upfront payment. Philochem ...

Rep Kim Schrier, MD, (D-Wash.), said on X yesterday that some of the newly appointed ACIP replacements are anti-vaccine ...

Pfizer's RSV shot Abrysvo was cleared by the FDA last October for the 18 to 59 age group, extending its 2023 approval in the ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...